

What does VP.S Encore™ do?

- VP.S Encore™ greatly expands the window of time that an organ can remain viable for a transplant or re-attachment operation.
- Every 30 seconds a patient dies from diseases that could be treated with vascularized tissue replacement.
- With its ability to preserve and resuscitate vascularized tissue (organs) for more than 8 hours, VP.S Encore™ removes the geographic limitations associated with transportation.
- VP.S Encore™ helps remove time from the transplant equation and offers hope to patients awaiting organ transplants.

How long can VP.S Encore™ keep an organ alive?

- VP.S Encore™ is designed to preserve and resuscitate vascularized tissue (organs) for more than 8 hours.

Why does doubling the viability of an organ from 4 hours to 8 hours make such a difference?

- **More Organs:** More donated organs will be available because there's more time to reach patients.
- **Better Matches:** With more organs available, surgeons are able to select a better match, rather than settling for a possible match.
- **Fewer Rejections:** With more time, organs are in better condition at transplantation, rather than on the edge of viability.

Why isn't VP.S Encore™ already on the market?

- We are continuing to move through the research process and are working to obtain the FDA's approval of a new and improved version of ULISSES™, the VP.S Encore™ device.

How exactly does VP.S Encore™ work?

- VP.S Encore™ uses only a small oxygen cylinder for power and active perfusion, to allow transport of organs anywhere in the world.
- It is highly portable, single-use/disposable, simple to operate, light-weight, and inexpensive.
- It can easily be transported in a commercial airliner, stored in an overhead compartment, or under the seat.
- On the battlefield, the VP.S Encore™ device offers a flexible casing option using the same fluid carried by medics in common IV bags, to preserve an avulsed hand, arm, or leg until a warfighter can have it reattached at a regular hospital.

What is the current method of organ preservation? / Why is VP.S Encore™ better for preserving organs than the current technology?

- Currently, the most commonly used and accepted method for organ transport and preservation is an ice chest, which offers no oxygenation, only insulation. Ice—dry, frozen or Blu—is used in the cooler to slow down the deterioration process.
- VP.S Encore™ perfuses tissue with oxygenated fluid, allowing an organ to be viable for more than 8 hours. This enables the organ to be transported to anywhere in the world to a patient awaiting treatment or transplant.
- VP.S Encore™ dramatically increases the time available for transplant operations.

How much will a patient have to pay to use one of these devices?

- The cost per patient will vary depending on their insurance coverage.

When will this device come out on the open market?

- This will depend on obtaining the FDA's clearance to make VP.S Encore™ available to the public.
- In early 2021, the FDA granted VPS a Breakthrough Device Designation for the VP.S Encore™ device. VPS now has the priority to interact more quickly with the FDA, moving us closer to bringing VP.S Encore™ and its lifesaving technology to patients across the country, and eventually, the world.

What has to happen before you can start selling these?

- We must move through the research process and obtain the FDA's permission to get the VP.S Encore™ device into early clinical use. As soon as the FDA allows, VP.S Encore™ will apply for clearance to make the device available to the public.
- Even so at this stage, VP.S Encore™ is fully functional for research purposes.

What/who is VPS? How is it associated with the VP.S Encore™ device?

- Vascular Perfusion Solutions, Inc. (VPS) is a development and early-stage company, formed for the purpose of commercializing new, unique, and innovative Oxygenated Perfusion Solutions for the body's organs and other vascularized tissues.
- The primary goal of VPS is to extend life, and enhance its quality. In the development of VP.S Encore™, we aim to improve the quality-of-life of patients awaiting organ transplant by removing obstacles that can impede or delay their treatment and healing.

What kind of research will you be conducting?

- The VP.S Encore™ device has already been successfully tested in small and large animal studies. The next step is to conduct animal studies, followed by human testing. This will provide the data needed for early FDA submission to secure FDA approval.